|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Malik P, Chaudhry N, Mittal R and
Mukherjee TK: Role of receptor for advanced glycation end products
in the complication and progression of various types of cancers.
Biochim Biophys Acta. 1850:1898–1904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jules J, Maiguel D and Hudson BI:
Alternative splicing of the RAGE cytoplasmic domain regulates cell
signaling and function. PLoS One. 8:e782672013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen X, Zhang L, Zhang IY, Liang J, Wang
H, Ouyang M, Wu S, da Fonseca ACC, Weng L, Yamamoto Y, et al: RAGE
expression in tumor-associated macrophages promotes angiogenesis in
glioma. Cancer Res. 74:7285–7297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Elangovan I, Thirugnanam S, Chen A, Zheng
G, Bosland MC, Kajdacsy-Balla A and Gnanasekar M: Targeting
receptor for advanced glycation end products (RAGE) expression
induces apoptosis and inhibits prostate tumor growth. Biochem
Biophys Res Commun. 417:1133–1138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalea AZ, See F, Harja E, Arriero M,
Schmidt AM and Hudson BI: Alternatively spliced RAGEv1 inhibits
tumorigenesis through suppression of JNK signaling. Cancer Res.
70:5628–5638. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kang R, Tang D, Schapiro NE, Livesey KM,
Farkas A, Loughran P, Bierhaus A, Lotze MT and Zeh HJ: The receptor
for advanced glycation end products (RAGE) sustains autophagy and
limits apoptosis, promoting pancreatic tumor cell survival. Cell
Death Differ. 17:666–676. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yin C, Li H, Zhang B, Liu Y, Lu G, Lu S,
Sun L, Qi Y, Li X and Chen W: RAGE-binding S100A8/A9 promotes the
migration and invasion of human breast cancer cells through actin
polymerization and epithelial-mesenchymal transition. Breast Cancer
Res Treat. 142:297–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tseng JH, Bisogna M, Hoang LN, Olvera N,
Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Levine DA and
Jelinic P: miR-200c-driven Mesenchymal-To-Epithelial Transition is
a Therapeutic Target in Uterine Carcinosarcomas. Sci Rep.
7:36142017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siemens H, Jackstadt R, Hünten S, Kaller
M, Menssen A, Götz U and Hermeking H: miR-34 and SNAIL form a
double-negative feedback loop to regulate epithelial-mesenchymal
transitions. Cell Cycle. 10:4256–4271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S,
Seo AN, Lee HJ and Park SY: MicroRNA-9 is associated with
epithelial-mesenchymal transition, breast cancer stem cell
phenotype, and tumor progression in breast cancer. Breast Cancer
Res Treat. 147:39–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li S, Ma Y, Hou X, Liu Y, Li K, Xu S and
Wang J: MiR-185 acts as a tumor suppressor by targeting AKT1 in
non-small cell lung cancer cells. Int J Clin Exp Pathol.
8:11854–11862. 2015.PubMed/NCBI
|
|
15
|
Yoon JH, Choi YJ, Choi WS, Ashktorab H,
Smoot DT, Nam SW, Lee JY and Park WS: GKN1-miR-185-DNMT1 axis
suppresses gastric carcinogenesis through regulation of epigenetic
alteration and cell cycle. Clin Cancer Res. 19:4599–4610. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang R, Tian S, Wang HB, Chu DP, Cao JL,
Xia HF and Ma X: MiR-185 is involved in human breast carcinogenesis
by targeting Vegfa. FEBS Lett. 588:4438–4447. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang H, Wang Z, Liu X, Liu Q, Xu G, Li G
and Wu M: LRRC4 inhibits glioma cell growth and invasion through a
miR-185-dependent pathway. Curr Cancer Drug Targets. 12:1032–1042.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jing R, Chen W, Wang H, Ju S, Cong H, Sun
B, Jin Q, Chu S, Xu L and Cui M: Plasma miR-185 is decreased in
patients with esophageal squamous cell carcinoma and might suppress
tumor migration and invasion by targeting RAGE. Am J Physiol
Gastrointest Liver Physiol. 309:G719–G729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Varlet AA, Fuchs M, Luthold C, Lambert H,
Landry J and Lavoie JN: Fine-tuning of actin dynamics by the
HSPB8-BAG3 chaperone complex facilitates cytokinesis and
contributes to its impact on cell division. Cell Stress Chaperones.
22:553–567. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi C, Cai Y, Li Y, Li Y, Hu N, Ma S, Hu
S, Zhu P, Wang W and Zhou H: Yap promotes hepatocellular carcinoma
metastasis and mobilization via governing
cofilin/F-actin/lamellipodium axis by regulation of
JNK/Bnip3/SERCA/CaMKII pathways. Redox Biol. 14:59–71. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fife CM, McCarroll JA and Kavallaris M:
Movers and shakers: Cell cytoskeleton in cancer metastasis. Br J
Pharmacol. 171:5507–5523. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Manetti F: LIM kinases are attractive
targets with many macromolecular partners and only a few small
molecule regulators. Med Res Rev. 32:968–998. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mali RS and Kapur R: Targeting Rho
associated kinases in leukemia and myeloproliferative neoplasms.
Oncotarget. 3:909–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Okamoto I, Pirker C, Bilban M, Berger W,
Losert D, Marosi C, Haas OA, Wolff K and Pehamberger H: Seven novel
and stable translocations associated with oncogenic gene expression
in malignant melanoma. Neoplasia. 7:303–311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mardilovich K, Gabrielsen M, McGarry L,
Orange C, Patel R, Shanks E, Edwards J and Olson MF: Elevated LIM
kinase 1 in nonmetastatic prostate cancer reflects its role in
facilitating androgen receptor nuclear translocation. Mol Cancer
Ther. 14:246–258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhi Q, Zhu J, Guo X, He S, Xue X, Zhou J,
Hu B, Li H, Chen S, Zhao H and Kuang Y: Metastasis-related miR-185
is a potential prognostic biomarker for hepatocellular carcinoma in
early stage. Biomed Pharmacother. 67:393–398. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Osbourne A, Calway T, Broman M, McSharry
S, Earley J and Kim GH: Downregulation of connexin43 by
microRNA-130a in cardiomyocytes results in cardiac arrhythmias. J
Mol Cell Cardiol. 74:53–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liao X, Xue H, Wang YC, Nazor KL, Guo S,
Trivedi N, Peterson SE, Liu Y, Loring JF and Laurent LC: Matched
miRNA and mRNA signatures from an hESC-based in vitro model of
pancreatic differentiation reveal novel regulatory interactions. J
Cell Sci. 126:3848–3861. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
James EN, Delany AM and Nair LS:
Post-transcriptional regulation in osteoblasts using localized
delivery of miR-29a inhibitor from nanofibers to enhance
extracellular matrix deposition. Acta Biomater. 10:3571–3580. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qiu F, Xiong JP, Deng J and Xiang XJ:
TRIM29 functions as an oncogene in gastric cancer and is regulated
by miR-185. Int J Clin Exp Pathol. 8:5053–5061. 2015.PubMed/NCBI
|
|
32
|
Qadir XV, Han C, Lu D, Zhang J and Wu T:
miR-185 inhibits hepatocellular carcinoma growth by targeting the
DNMT1/PTEN/Akt pathway. Am J Pathol. 184:2355–2364. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ponnusamy MP, Seshacharyulu P, Lakshmanan
I, Vaz AP, Chugh S and Batra SK: Emerging role of mucins in
epithelial to mesenchymal transition. Curr Cancer Drug Targets.
13:945–956. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu Y, Tran T, Dwabe S, Sarkissyan M, Kim
J, Nava M, Clayton S, Pietras R, Farias-Eisner R and Vadgama JV:
A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial
to mesenchymal transition in HER2-overexpressing breast cancer
cells. Breast Cancer Res Treat. 163:449–460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Batlle E, Sancho E, Francí C, Domínguez D,
Monfar M, Baulida J and De Herreros García A: The transcription
factor snail is a repressor of E-cadherin gene expression in
epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhai L, Ma C, Li W, Yang S and Liu Z:
miR-143 suppresses epithelial-mesenchymal transition and inhibits
tumor growth of breast cancer through down-regulation of ERK5. Mol
Carcinog. 55:1990–2000. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Hu L, Ji P, Teng F, Tian W, Liu Y,
Cogdell D, Liu J, Sood AK, Broaddus R, et al: Erratum to: MIIP
remodels Rac1-mediated cytoskeleton structure in suppression of
endometrial cancer metastasis. J Hematol Oncol. 10:1632017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Silva EJ, Argyris PP, Zou X, Ross KF and
Herzberg MC: S100A8/A9 regulates MMP-2 expression and invasion and
migration by carcinoma cells. Int J Biochem Cell Biol. 55:279–287.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Khammanivong A, Wang C, Sorenson BS, Ross
KF and Herzberg MC: S100A8/A9 (calprotectin) negatively regulates
G2/M cell cycle progression and growth of squamous cell carcinoma.
PLoS One. 8:e693952013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gebhardt C, Németh J, Angel P and Hess J:
S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol.
72:1622–1631. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ichikawa M, Williams R, Wang L, Vogl T and
Srikrishna G: S100A8/A9 activate key genes and pathways in colon
tumor progression. Mol Cancer Res. 9:133–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Saha A, Lee YC, Zhang Z, Chandra G, Su SB
and Mukherjee AB: Lack of an endogenous anti-inflammatory protein
in mice enhances colonization of B16F10 melanoma cells in the
lungs. J Biol Chem. 285:10822–10831. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dahlmann M, Okhrimenko A, Marcinkowski P,
Osterland M, Herrmann P, Smith J, Heizmann CW, Schlag PM and Stein
U: RAGE mediates S100A4-induced cell motility via MAPK/ERK and
hypoxia signaling and is a prognostic biomarker for human
colorectal cancer metastasis. Oncotarget. 5:3220–3233. 2014.
View Article : Google Scholar : PubMed/NCBI
|
